Cardiometabolic benefits of parathyroidectomy in dialysis patients with secondary hyperparathyroidism: preliminary insights from CT radiomics and body composition analysis.
Parathyroidectomy in dialysis patients with secondary hyperparathyroidism may improve certain cardiometabolic parameters, including changes in epicardial adipose tissue and bone density.
Where it sits
this study against the rest of the melanotan 1 corpusSummary and findings
This study evaluated the effects of parathyroidectomy (PTX) on epicardial adipose tissue (EAT) and cardiometabolic outcomes in dialysis patients with secondary hyperparathyroidism (SHPT). Participants underwent CT-based assessments, with significant findings at baseline and 6 months post-PTX. Results indicated changes in EAT parameters, bone mineral density, and coronary artery calcification progression.
Abstract
Secondary hyperparathyroidism (SHPT) contributes to mineral-bone disorders, chronic inflammation, and adverse cardiometabolic outcomes in patients undergoing dialysis. Radiomics of epicardial adipose tissue (EAT) derived from computed tomography (CT) may serve as an imaging biomarker of cardiometabolic risk; however, the effect of parathyroidectomy (PTX) on EAT remodeling remains unclear. This cohort study enrolled dialysis patients with severe SHPT who underwent PTX and controls who received standard medical therapy. At baseline and 6 months, the participants underwent CT-based EAT radiomics assessment, coronary artery calcification (CAC) scoring, dual-energy X-ray absorptiometry (DEXA) for body composition and bone mineral density (BMD), and biochemical evaluation. PTX significantly decreased EAT attenuation (-69.99 ± 8.07 to -72.64 ± 5.68 HU; <i>p </i>= 0.04) and increased EAT volume (<i>p</i> = 0.04), indicating a shift toward less inflamed, lipid-rich adipose tissue. Fat mass and BMD increased (<i>p</i> < 0.01), whereas lean mass and resting metabolic rate decreased (<i>p</i> < 0.01). Controls exhibited stable EAT parameters but showed significant BMD decline (<i>p</i> = 0.02) and CAC progression (<i>p</i> = 0.005). PTX was associated with significantly lower CAC progression according to both the Hokanson and Modified Raggi criteria (<i>p</i> < 0.05). Changes in EAT volume were negatively correlated with changes in attenuation (<i>r</i> = -0.444, <i>p </i>= 0.006). These findings suggest that PTX in dialysis patients with SHPT might modulate cardiometabolic profiles by increasing EAT volume, reducing EAT attenuation, improving bone density, and attenuating CAC progression. Furthermore, CT-derived EAT radiomics may provide complementary biomarkers for cardiometabolic remodeling following PTX.
Background
This paper addresses the impact of secondary hyperparathyroidism (SHPT) on cardiometabolic health in dialysis patients, a known contributor to mineral-bone disorders and inflammation. Previous studies have suggested that parathyroidectomy (PTX) may influence these outcomes, but the specific effects on epicardial adipose tissue (EAT) and overall cardiometabolic profiles were not well understood. This study aims to clarify the role of PTX in modifying EAT and related cardiometabolic risk factors.
Methods
This cohort study included dialysis patients with severe SHPT who underwent PTX and a control group receiving standard medical therapy. Participants were assessed at baseline and 6 months using CT for EAT radiomics, coronary artery calcification (CAC) scoring, dual-energy X-ray absorptiometry (DEXA) for body composition and bone mineral density (BMD), and biochemical evaluations. The primary outcomes included changes in EAT attenuation and volume, while secondary outcomes involved BMD and CAC progression.
Results
The primary endpoint showed that EAT attenuation significantly decreased from -69.99 ± 8.07 to -72.64 ± 5.68 HU (p=0.04) after PTX. Additionally, EAT volume increased (p=0.04), while fat mass and BMD increased (p<0.01). Lean mass and resting metabolic rate decreased (p<0.01). The control group exhibited a significant decline in BMD (p=0.02) and CAC progression (p=0.005).
Interpretation
These findings suggest that PTX may have a beneficial effect on EAT parameters and cardiometabolic profiles in dialysis patients with SHPT. However, while the changes in EAT attenuation and volume are statistically significant, the clinical significance of these changes remains uncertain. The study is limited by its cohort design, and the relatively short follow-up period may not adequately reflect the long-term benefits of PTX.
Key findings
- -69.99 ± 8.07 to -72.64 ± 5.68 HU EAT attenuation, p=0.04
- EAT volume increased, p=0.04
- Fat mass and BMD increased, p<0.01
- Lean mass and resting metabolic rate decreased, p<0.01
- Controls showed significant BMD decline, p=0.02
- CAC progression in controls, p=0.005
Limitations
- small sample size not reported
- 6-month follow-up may not capture long-term effects
- single-site study limits generalizability
- no randomization reported
- not blinded